Isolation-infusion effective with melanoma in sarcoma: Good alternative for regional isolation perfuse with cytostatic;Isolatie-infusie effectief bij melanoom en sarcoom: Goed alternate voor regionaleisolatieperfusie met cytostatica

Nederlands Tijdschrift voor Geneeskunde

Volumn 153, Issue 11, 2009, Pages 508-514

  Kroon, Hidde M ^a   Thompson, John F ^a,b   Hoekstra, Harald J ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSTATIC AGENT; DACTINOMYCIN; MELPHALAN;

HUMAN; MELANOMA; REVIEW; SARCOMA; TOURNIQUET; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; EXTREMITIES; HUMANS; INFUSION PUMPS; MELANOMA; SARCOMA; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 62949163752     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al, Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635-48.
2. Hoekstra HJ. The European approach to in-transit melanoma lesions. Int J Hyperthermia. 2008;26:227-37.
3. Hoekstra HJ. Extremity perfusion for sarcoma. Surg Oncol Clin N Am. 2008;17:805-24.
4. Vrouenraets BC, Nieweg OE, Kroon BB. Thirty-five years of isolated limb perfusion for melanoma: indications and results. Br J Surg. 1996;83:1319-28.
5. Van Ginkel RJ, Limburg PC, Piers DA, Koops HS, Hoekstra HJ. Value of continuous leakage monitoring with radioactive iodine-131-labeled human serum albumin during hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan. Ann Surg Oncol. 2002;9:355-63.
6. Grünhagen DJ, de Wilt JH, van Geel AN, Eggermont AM. Isolated limb perfusion for melanoma patients-a review of its indications and the role of tumour necrosis factor-alpha. Eur J Surg Oncol. 2006;32:371-80.
7. Noorda EM, Vrouenraets BC, Nieweg OE, van Coevorden F, van Slooten GW, Kroon BB. Isolated limb perfusion with tumor necrosis factor-alpha and melphalan for patients with unresectable soft tissue sarcoma of the extremities. Cancer. 2003;98:1483-90.
8. Thompson JF, de Wilt JH. Isolated limb perfusion in the management of patients with recurrent limb melanoma: an important but limited role. Ann Surg Oncol. 2001;8:564-5.
9. Noorda EM, Vrouenraets BC, Nieweg OE, van Geel AN, Eggermont AM, Kroon BB. Safety and efficacy of isolated limb perfusion in elderly melanoma patients. Ann Surg Oncol. 2002;9:968-74.
10. Van Etten B, van Geel AN, de Wilt JH, Eggermont AM. Fifty tumor necrosis factor-based isolated limb perfusions for limb salvage in patients older than 75 years with limb-threatening soft tissue sarcomas and other extremity tumors. Ann Surg Oncol. 2003;10:32-7.
11. McMasters KM. Isolated limb perfusion in elderly melanoma patients. Ann Surg Oncol. 2002;9:939-40.
12. Thompson JF,Waugh RC, Saw RP, Kam PC. Isolated limb infusion with melphalan for recurrent limb melanoma. A simple alternative to isolated limb perfusion. Reg Cancer Treat. 1994;7:188-92.
13. Kroon HM, Moncrieff M, Kam PC, Thompson JF. Outcomes following isolated limb infusion for melanoma. A 14-year experience. Ann Surg Oncol. 2008;15:2987-90.
14. Roberts MS, Wu ZY, Siebert GA, Anissimov YG, Thompson JF, Smithers BM. Pharmacokinetics and pharmacodynamics of melphalan in isolated limb infusion for recurrent localized limb malignancy. Melanoma Res. 2001;11:423-31.
15. Karakousis CP, Kanter PM, Park HC, Sharma SD, Moore R, Ewing JH. Tourniquet infusion versus hyperthermic perfusion. Cancer. 1982;49:850-8.
16. Thompson JF, Hunt JA, Shannon KF, Kam PC. Frequency and duration of remission after isolated limb perfusion for melanoma. Arch Surg. 1997;132:903-7.
17. Thompson JF, Kam PC, Waugh RC, Harman CR. isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion. Semin Surg Oncol. 1998;14:238-47.
18. Grünhagen DJ, Brunstein F, Graveland WJ, van Geel AN, de Wilt JH, Eggermont AM. One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-transit metastases. Ann Surg. 2004;240:939-47.
19. Noorda EM, Vrouenraets BC, Nieweg OE, van Geel BN, Eggermont AM, Kroon BB. Isolated limb perfusion for unresectable melanoma of the extremities. Arch Surg. 2004;139:1237-42.
20. Brady MS, Brown K, Patel A, Fisher C, Marx W. A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity. Ann Surg Oncol. 2006;13:1123-9.
21. Mian R, Henderson MA, Speakman D, Finkelde D, Ainslie J, McKenzie A. Isolated limb infusion for melanoma: a simple alternative to isolated limb perfusion. Can J Surg. 2001;44:189-92.
22. Hegazy MA, Kotb SZ, Sakr H, El Dosoky E, Amer T, Hegazi RA, et al. Preoperative isolated limb infusion of Doxorubicin and external irradiation for limb-threatening soft tissue sarcomas. Ann Surg Oncol. 2007;14:568-76.
23. Ryan ER, Hill AD, Skehan SJ. FDG PET/CT demonstrates the effectiveness of isolated limb infusion for malignant melanoma. Clin Nucl Med. 2006;31:707-8.
24. Beasley GM, Petersen RP, Yoo J, McMahon N, Aloia T, Petros W, et al. Isolated limb infusion for in-transit malignant melanoma of the extremity: a well tolerated but less effective alternative to hyperthermic isolated limb perfusion. Ann Surg Oncol. 2008;15:2195-205.
25. Lindnér P, Doubrovsky A, Kam PC, Thompson JF. Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma. Ann Surg Oncol. 2002;9:127-36.
26. Moncrieff MD, Kroon HM, Kam PC, Stalley PD, Scolyer RA, Thompson [F. Isolated limb infusion for advanced soft tissue sarcoma of the extremity. Ann Surg Oncol. 2008;15:2749-56.
27. Lindnér P, Thompson JF, de Wilt JH, Colman M, Kam PC. Double isolated limb infusion with cytotoxic agents for recurrent and metastatic limb melanoma. Eur J Surg Oncol. 2004;30:433-9.
28. Siemann DW, Chapman M, Beikirch A. Effects of oxygenation and pH on tumor cell response to alkylating chemotherapy. Int J Radiat Oncol Biol Phys. 1991;20:287-9.
29. Yoshimoto Y, Augustine CK, Yoo JS, Zipfel PA, Selim MA, Pruitt SK, et al. Defining regional infusion treatment strategies for extremity melanoma: comparative analysis of melphalan and temozolomide as regional chemotherapeutic agents. Mol Cancer Ther. 2007;6:1492-500.
30. Beasley GM, Ross MI, Tyler DS. Future directions in regional treatment strategies for melanoma and sarcoma. Int J Hyperthermia. 2008;24:301-9.